IP Library Granted Patent US 9,114,068
Granted Patent B2
US 9,114,068 · App. 14/264,267 · Granted Aug 25, 2015

Treating patients with intravenous ibuprofen

Inventors: Leo Pavliv (Cary, NC); Amy Dix Rock (Thompson Station, TN)
Assignee: Cumberland Pharmaceuticals, Inc.
A61K9/0019A61K31/19A61K31/192A61K31/198
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,114,068
App. No.
14/264,267
Granted
Aug 25, 2015
Kind
B2
Abstract

Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.

Claims (14)

1. A method of treating pain in human patients in need thereof, comprising administering to the human patients an intravenous ibuprofen pharmaceutical composition in an effective dose from about 400 mg to about 800 mg about every 4 to about 6 hours to treat pain, wherein the patients suffer from high blood pressure and do not suffer from inflammation, such that the mean arterial pressure of the patients does not increase during the dosage.

2. The method of claim 1 , wherein the patients are critically ill, and the dose of ibuprofen administered attains a mean Cmax of about 20.8 μg/ml to about 75 μg/ml.

3. The method of claim 2 , wherein the administered intravenous ibuprofen pharmaceutical composition attains a mean AUC of about 36.8 μg·h/ml to about 117.5 μg·h/ml.

4. The method of claim 1 , wherein the ibuprofen pharmaceutical composition is an aqueous solution of arginine and ibuprofen.

5. The method of claim 4 , wherein the molar ratio of arginine to ibuprofen is selected from less than or equal to 1:1, less than or equal to 0.99:1, less than or equal to 0.98:1, less than or equal to 0.97:1, less than or equal to 0.96:1, less than or equal to 0.95:1, less than or equal to 0.94:1, less than or equal to 0.93:1, less than or equal to 0.92:1, less than or equal to 0.91:1, less than or equal to 0.90:1, less than or equal to 0.60:1.

6. The method of claim 1 , comprising administering the dose of ibuprofen to the patients about every 6 hours.

7. The method of claim 2 , wherein the critically ill patients are patients receiving a treatment selected from the group consisting of vasopressor support, mechanical ventilation, dialysis, multiple antibiotics, pulmonary artery catheter or arterial blood pressure catheter, and combinations of any of the foregoing.

8. The method of claim 1 , wherein the dose of ibuprofen pharmaceutical composition administered is selected from the group consisting of 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, and 800 mg.

9. The method of claim 1 , wherein the dose of the ibuprofen pharmaceutical composition is administered over 30 minutes.

10. The method of claim 1 , wherein the dose of the ibuprofen pharmaceutical composition is about 800 mg.

11. The method of claim 1 , wherein the dose of the ibuprofen pharmaceutical composition is about 400 mg.

12. The method of claim 2 , wherein the critically ill patients are patients being treated in an Intensive Care Unit.

13. The method of claim 2 , wherein the critically ill patients are being administered packed red blood cells.

14. The method of claim 1 , comprising administering the dose of the ibuprofen pharmaceutical composition to the patients about every 4 hours.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2026
From: CUMBERLAND PHARMACEUTICALS INC.
To: APOTEX CORP.
Reel/Frame 075763/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2014
From: PAVLIV, LEO; ROCK, AMY DIX
To: CUMBERLAND PHARMACEUTICALS, INC.
Reel/Frame 032838/0718 →
Continuity (7)
Continuation 12699595 · Feb 3, 2010
Continuation In Part 12646499 · Dec 23, 2009
Continuation In Part 12570912 · Sep 30, 2009
Provisional Application 61230324 · Jul 31, 2009
Provisional Application 61230342 · Jul 31, 2009
Provisional Application 61225778 · Jul 15, 2009
Related Publication 20140235720A1 · Aug 21, 2014